CYT-1010

CYT-1010 is a novel analgesic and the first member of the endomorphin class to reach clinical development. It is a cyclized D-Lys-containing analog of endomorphin-1 that acts as a highly selective mu-opioid receptor (MOR) agonist with preferential binding to both traditional mu-opioid receptors and truncated splice variants (6TM) initiated at Exon 11. This unique mechanism allows for potent pain relief with significantly reduced risk of addiction and respiratory depression compared to classical opioids. Preclinical studies have shown that CYT-1010 provides 3–4 times more potent analgesia than morphine, has anti-inflammatory properties, minimal abuse potential, and little or no respiratory depression even at high doses. The drug is being developed for moderate to severe pain management—including acute pain—and may also be effective in neuropathic and inflammatory pain conditions[1][2][6][8].

Other names

CYT-1010 hydrochlorideCYT1010 hydrochlorideCYT 1010 hydrochlorideHY-123534AHY123534AHY 123534ADA-62613DA62613DA 626131161517-81-2